Arrowhead Jumps in Anticipation of Analyst Day
Arrowhead Research shares soared in early trading indications Thursday in anticipation of its analyst day.
Arrowhead Research Corp. (NASDAQ: ARWR) shares soared in early trading indications Thursday in anticipation of its analyst day. The company is hosting the event Thursday in New York, with its presentation starting at 11:00 a.m. Eastern. This event was set up to discuss top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection.
Also, Arrowhead will discuss findings from an ARC-520 study with a background therapy of nucleotide/nucleoside analog inhibitors (NUCs) tenofovir and/or entecavir.
In its release, Arrowhead listed a few of its key findings as follows:
- Arrowhead’s proprietary DPC platform can effectively and consistently knock down target genes in humans.
- ARC-520 achieves significant HBV s-Antigen (HBsAg) reductions in humans, particularly in treatment naïve, HBeAg-positive patients.
- Arrowhead identifies a large target HBV population for ARC-520 and describes a new paradigm for the HBV lifecycle.
- ARC-520 induces deep HBsAg reduction in chronically HBV infected chimps and one of four HBeAg-positive chimps demonstrated signs of immune reactivation during therapy.
- ARC-520 has been well tolerated.
- Arrowhead expands its HBV portfolio by nominating an additional clinical candidate that is complementary to ARC-520.
Arrowhead Research is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes.
ALSO READ: 10 Cities Where You Don’t Want to Get Sick
Christopher Anzalone, Ph.D., president and CEO of Arrowhead, said:
These are exciting data that represent a significant leap forward for our DPC platform, ARC-520, and the HBV field. We have achieved the highest knockdown ever reported in humans with RNAi and a safety profile that continues to be excellent. We are optimistic that this will ultimately translate into powerful clinical outcomes for ARC-520 and follow-on candidates against multiple indications.
Shares of Arrowhead closed Wednesday down 4.4%, at $6.74 in its 52-week trading range of $4.35 to $15.88. In early trading indications Thursday, shares were up over 44% at $9.72. The stock has a consensus analyst price target of $9.50.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
